The FDA has expanded the indication for Toujeo (insulin glargine; Sanofi) 300 Units/mL to include treatment of pediatric patients aged ≥6 years with diabetes mellitus.
The high prevalence of overweight and obesity in youth with T1D was consistent across a multinational cohort and persistent over time.
Adjusting glucose thresholds for hypoglycemia and hyperglycemia alarms in continuous glucose monitoring can help achieve better glucose control in patients with type 1 diabetes.
For patients with newly diagnosed type 2 diabetes, visit-to-visit HbA1c variability is associated with increased risks for cardiovascular disease and microvascular complications.
Sleep may be an important modifiable factor in disease management in patients with type 2 diabetes, especially variation in sleep duration.
Taking certain antidepressants while pregnant can increase the risk for developing gestational diabetes.
Short-term weight loss improves β-cell function in patients with obesity who have either normal or impaired fasting glucose, but despite initial improvements, β-cell function commonly deteriorates over the course of 2 years.
Breastfeeding for >12 months was found to be associated with a reduced risk for hypertension and diabetes.
Nationwide, about half of Medicare fee-for-service beneficiaries with diabetes had eye exams in 2017.
Treatment with canagliflozin was associated with similar reductions in HbA1c compared with any dose of a GLP-1 receptor agonist, with better treatment adherence and lower annual costs.